ProCE Banner Activity

NRG Oncology/NSABP B-51/RTOG 1304: Phase III Trial Evaluating Benefit of Adjuvant Regional Nodal Irradiation in Patients With Early Breast Cancer Converting to Axillary Lymph Node Negativity After Neoadjuvant Chemotherapy

Conference Coverage

In patients with clinically lymph node–positive early breast cancer who convert to axillary lymph node negativity after neoadjuvant chemotherapy, omitting adjuvant regional nodal irradiation after surgery did not appear to compromise clinical outcomes with a median follow-up of 59.5 months.

Released: December 08, 2023


Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc., Gilead Sciences, Inc., Lilly, Merck Sharp & Dohme LLC, and Seagen Inc.


Daiichi Sankyo, Inc.

Gilead Sciences, Inc.


Merck Sharp & Dohme, LLC

Seagen Inc.